Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| (NASDAQ: ARVN) | Delayed: 7.58 -0.06 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.64 | 52 Week High | $ | |||
| Open | $7.73 | 52 Week Low | $ | |||
| Day High | $7.73 | P/E | N/A | |||
| Day Low | $7.52 | EPS | $ | |||
| Volume | 60,675 | |||||
